Claris Life gets USFDA nod for generic anesthetic injection
New Delhi : Drug firm Claris Lifesciences has received approval from the US health regulator for generic anesthetic Bupivacaine injection.
The company has received approval from the United States Food and Drug Administration (USFDA) for generic "Bupivacaine hydrochloride in 8.25 per cent dextrose injection USP 7.5 mg/mL, single dose ampules with 2 ml fill volumes," Claris Lifesciences said in a BSE filing.
The injection is indicated for the production of local or regional anesthesia or analgesia for surgery, diagnostic and therapeutic procedures.
With this approval the company has 15 approvals and 25 under approval abbreviated new drug applications (ANDAs), Claris Lifesciences said.
The company expects more product approvals during the year, it added.
Shares of Claris Lifesciences were trading at Rs 253.60 in the afternoon trade on BSE, up 1.02 per cent.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd